store at low temperature
store at -80°C
Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 255.00 | |
5 mg | In stock | $ 668.00 | |
10 mg | In stock | $ 1,070.00 | |
25 mg | In stock | $ 1,590.00 | |
50 mg | In stock | $ 2,130.00 | |
100 mg | In stock | $ 2,890.00 |
Description | Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN). |
In vivo | Treatment with Lirilumab (intravenous injection; once; 15 mg/kg) enhances the survival rate of mice injected with tumor[1]. |
Synonyms | ONO-4483, IPH2102 |
Molecular Weight | N/A |
CAS No. | 1000676-41-4 |
store at low temperature
store at -80°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lirilumab 1000676-41-4 Microbiology/Virology Virus Protease ONO-4483 ONO 4483 IPH-2102 IPH2102 ONO4483 IPH 2102 inhibitor inhibit